Big Investor Demand for OrbiMed Life Science Investment Funds Leads to $3.5B Raise

Big Investor Demand for OrbiMed Life Science Investment Funds Leads to $3.5B Raise

Founded back in 1989 in New York City, OrbiMed has become a life science investment powerhouse, representing one of the world’s leading venture capital firms investing in new, breakthrough therapies. Most recently, the investor announced $3.5 billion in commitments for its private investment funds. The new funds and injection of capital brings this firm’s assets under management up to about $18 billion across public equity, private equity and credit/royalty states. OrbiMed positions itself as an active investor, combining capital with complementary team capabilities in a quest to partner with management teams in building the next generation of world-class healthcare companies. TrialSite offers a summary breakdown of  the recent investor commitments and looks at their track record as compared to other investment firms across various life science investment benchmarks.

During the pandemic, a few sectors will continue to experience huge investor demand and that includes life science activity such as biotech and pharmaceutical ventures. Evidencing this insatiable demand are the latest numbers reported by the investment firm, with offices in America, China, India and Israe...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee